14.13

0.21% -0.03

After Hours: 14.13

Trevi Therapeutics Inc (TRVI)

Overview News Price History Option Chain Financials Discussions Forecast

Trevi Therapeutics Inc stock is traded at $14.13, with a volume of 1.32M. It is down -0.21% in the last 24 hours and down -4.53% over the past month. Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Previous Close:

$14.16

Open:

$14.23

24h Volume:

1.32M

Relative Volume:

0.88

Market Cap:

$2.01B

Revenue:

Net Income/Loss:

$-45.61M

P/E Ratio:

-43.68

EPS:

-0.3235

Net Cash Flow:

$-45.40M

1W Performance:

-0.49%

1M Performance:

-4.53%

6M Performance:

+28.57%

1Y Performance:

+134.33%

1-Day Range:

$14.12

$14.49

1-Week Range:

$13.12

$14.49

52-Week Range:

$5.3801

$16.12

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Name

Trevi Therapeutics Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

203-304-2499

Address

195 CHURCH STREET, NEW HAVEN, CT

Employee

Twitter

@TreviThera

Next Earnings Date

2026-05-05

Latest SEC Filings

TRVI's Discussions on Twitter

Compare TRVI vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRVI Trevi Therapeutics Inc	14.13	2.01B	0	-45.61M	-45.40M	-0.3235
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-13-25	Initiated	Leerink Partners	Outperform
Aug-21-25	Initiated	Morgan Stanley	Overweight
Jul-01-25	Initiated	Cantor Fitzgerald	Overweight
May-28-25	Initiated	H.C. Wainwright	Buy
Mar-10-25	Reiterated	Needham	Buy
Mar-10-25	Upgrade	Raymond James	Outperform → Strong Buy
Dec-12-24	Reiterated	H.C. Wainwright	Buy
Sep-09-24	Resumed	Leerink Partners	Outperform
Aug-30-24	Initiated	H.C. Wainwright	Buy
Aug-30-24	Initiated	Raymond James	Outperform
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Apr-12-23	Initiated	B. Riley Securities	Buy
Nov-22-22	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	BMO Capital Markets	Outperform
Jun-03-19	Initiated	Needham	Buy
Jun-03-19	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	Stifel	Buy

View All

Trevi Therapeutics Inc Stock (TRVI) Latest News

May 24, 2026

Clear Street Maintains Trevi Therapeutics (TRVI) Buy Recommendation - MSN

May 24, 2026

May 20, 2026

Trevi Therapeutics Announces Proposed Public Offering of Common Stock - Quantisnow

May 20, 2026

TRVI Reiterated by Needham -- Price Target Maintained at $23 - GuruFocus

May 20, 2026

TRVI News | TREVI THERAPEUTICS INC (NASDAQ:TRVI) - ChartMill

May 20, 2026

May 19, 2026

Trevi Therapeutics stock (US89357P1049): short interest remains high as Wall Street targets signal u - AD HOC NEWS

May 19, 2026

May 18, 2026

Trevi Therapeutics maps Haduvio chronic cough push, sees cash runway into 2030 - MSN

May 18, 2026

May 17, 2026

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - GuruFocus

May 17, 2026

May 15, 2026